Cellular Biomedicine Group


$349.9m market cap

$17.25 last close

Cellular Biomedicine Group is a biotechnology company developing cell-based therapeutics with operations primarily in China.

Investment summary

Cellular Biomedicine Group (CBMG) announced it has signed an exclusive partnership with Novartis to manufacture the CAR-T therapy Kymriah in China. Novartis retains all marketing responsibility and CBMG will be entitled to both a mark-up on manufacturing costs and an escalating single-digit royalty on sales. Additionally, Novartis will take an equity stake in CBMG of approximately 9%: $40m at $27.43/share. Our valuation is lifted to $535m (from $353.1m).

Y/E Dec
Revenue (US$m)
PBT (US$m)
EPS (fd) (c)
P/E (x)
P/CF (x)
2016A 0.6 (15.7) (18.1) (134.30) N/A N/A
2017A 0.3 (19.2) (20.1) (140.41) N/A N/A
2018E 0.1 (22.7) (27.1) (143.01) N/A N/A
2019E 5.3 (17.5) (21.6) (108.59) N/A N/A
Last updated on 23/05/2019
Share price graph
Balance sheet
Forecast net cash (US$m) 30.3
Forecast gearing ratio (%) N/A
Price performance
Actual (2.7) (3.8) (2.3)
Relative* 1.2 (4.9) (5.3)
52-week high/low US$23.6/US$12.3
*% relative to local index
Key management
Terry A Belmont Chairman
Sarah Kelly Director of Corporate Communications
Tony (Bizuo) Liu Executive Officer and interim CFO